A Novel Four-Gene Signature Based on Nonsense-Mediated RNA Decay for Predicting Prognosis in Hepatocellular Carcinoma: Bioinformatics Analysis and Functional Validation

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2362–2368. doi:10.1158/1055-9965.EPI-11-0643
   PubMed Web of Science ®Google Scholar
• Van Thiel DH, Ramadori G. Non-viral causes of hepatocellular carcinoma. J Gastrointest Cancer. 2011;42(4):191–194. doi:10.1007/s12029-010-9195-3
   PubMedGoogle Scholar
• Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Li JJ, Liang Q, Sun GC. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: a focus on epithelial-mesenchymal transition. J Integr Med. 2021;19(6):469–477. doi:10.1016/j.joim.2021.08.004
   PubMed Web of Science ®Google Scholar
• Ran G, Feng X-L, Xie Y-L, et al. The use of miR122 and its target sequence in adeno-associated virus-mediated trichosanthin gene therapy. J Integr Med. 2021;19(6):515–525. doi:10.1016/j.joim.2021.09.004
   PubMedGoogle Scholar
• Xing M, Wang X, Kirken R, et al. Immunodiagnostic biomarkers for hepatocellular carcinoma (HCC): the first step in detection and treatment. Int J Mol Sci. 2021;22(11):6139. doi:10.3390/ijms22116139
   PubMed Web of Science ®Google Scholar
• Nault JC, Villanueva A. Intratumor molecular and phenotypic diversity in hepatocellular carcinoma. Clin Cancer Res. 2015;21(8):1786–1788. doi:10.1158/1078-0432.CCR-14-2602
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Sawada Y, Endo I, et al. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2015;21(37):10573–10583. doi:10.3748/wjg.v21.i37.10573
   PubMed Web of Science ®Google Scholar
• Popp MW, Maquat LE. Nonsense-mediated mRNA decay and cancer. Curr Opin Genet Dev. 2018;48:44–50. doi:10.1016/j.gde.2017.10.007
   PubMed Web of Science ®Google Scholar
• Kurosaki T, Popp MW, Maquat LE. Quality and quantity control of gene expression by nonsense-mediated mRNA decay. Nat Rev Mol Cell Biol. 2019;20(7):406–420. doi:10.1038/s41580-019-0126-2
   PubMed Web of Science ®Google Scholar
• Nickless A, Bailis JM, You Z. Control of gene expression through the nonsense-mediated RNA decay pathway. Cell Biosci. 2017;7:26. doi:10.1186/s13578-017-0153-7
   PubMed Web of Science ®Google Scholar
• Lindeboom RGH, Vermeulen M, Lehner B, et al. The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy. Nat Genet. 2019;51(11):1645–1651. doi:10.1038/s41588-019-0517-5
   PubMed Web of Science ®Google Scholar
• Schneppenheim R, Budde U, Obser T, et al. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. Blood. 2001;97(7):2059–2066. doi:10.1182/blood.V97.7.2059
   PubMed Web of Science ®Google Scholar
• Nogueira G, Fernandes R, García-Moreno JF, et al. Nonsense-mediated RNA decay and its bipolar function in cancer. Mol Cancer. 2021;20(1):72. doi:10.1186/s12943-021-01364-0
   PubMed Web of Science ®Google Scholar
• Bala S, Kraus C, Wijnen J, et al. Multiple products in the protein truncation test due to alternative splicing in the adenomatous polyposis coli (APC) gene. Hum Genet. 1996;98(5):528–533. doi:10.1007/s004390050254
   PubMed Web of Science ®Google Scholar
• Anczuków O, Ware MD, Buisson M, et al. Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? Hum Mutat. 2008;29(1):65–73. doi:10.1002/humu.20590
   PubMed Web of Science ®Google Scholar
• Chang L, Li C, Guo T, et al. The human RNA surveillance factor UPF1 regulates tumorigenesis by targeting Smad7 in hepatocellular carcinoma. J Exp Clin Cancer Res. 2016;35(1):8. doi:10.1186/s13046-016-0286-2
   PubMedGoogle Scholar
• Nagar P, Islam MR, Rahman MA. Nonsense-mediated mRNA decay as a mediator of tumorigenesis. Genes. 2023;14(2):357. doi:10.3390/genes14020357
   PubMed Web of Science ®Google Scholar
• Durand S, Cougot N, Mahuteau-Betzer F, et al. Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies. J Cell Biol. 2007;178(7):1145–1160. doi:10.1083/jcb.200611086
   PubMed Web of Science ®Google Scholar
• Iwatani-Yoshihara M, Ito M, Ishibashi Y, et al. Discovery and characterization of a eukaryotic initiation factor 4A-3-selective inhibitor that suppresses nonsense-mediated mRNA decay. ACS Chem Biol. 2017;12(7):1760–1768. doi:10.1021/acschembio.7b00041
   PubMed Web of Science ®Google Scholar
• Zhao J, Li Z, Puri R, et al. Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay. Mol Ther Nucleic Acids. 2022;27:304–318. doi:10.1016/j.omtn.2021.12.003
   PubMedGoogle Scholar
• Jardim DL, Goodman A, de Melo Gagliato D, et al. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–173. doi:10.1016/j.ccell.2020.10.001
   PubMed Web of Science ®Google Scholar
• Zhang H, Xia Y, Wang F, et al. Aldehyde dehydrogenase 2 mediates alcohol-induced colorectal cancer immune escape through stabilizing PD-L1 expression. Adv Sci. 2021;8(10):2003404. doi:10.1002/advs.202003404
   Web of Science ®Google Scholar
• Tian Z, Hong B, Chen J, et al. Combination of radiofrequency ablation with resiquimod to treat hepatocellular carcinoma via inflammation of tumor immune microenvironment and suppression of angiogenesis. Front Oncol. 2022;12:891724. doi:10.3389/fonc.2022.891724
   PubMed Web of Science ®Google Scholar
• Li X, Ramadori P, Pfister D, et al. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 2021;21(9):541–557. doi:10.1038/s41568-021-00383-9
   PubMed Web of Science ®Google Scholar
• Sun HC, Zhu XD. Downstaging conversion therapy in patients with initially unresectable advanced hepatocellular carcinoma: an overview. Front Oncol. 2021;11:772195. doi:10.3389/fonc.2021.772195
   PubMed Web of Science ®Google Scholar
• Nault JC, Villanueva A. Biomarkers for hepatobiliary cancers. Hepatology. 2021;73(1):115–127. doi:10.1002/hep.31175
   PubMedGoogle Scholar
• Tan K, Stupack DG, Wilkinson MF. Nonsense-mediated RNA decay: an emerging modulator of malignancy. Nat Rev Cancer. 2022;22(8):437–451. doi:10.1038/s41568-022-00481-2
   PubMed Web of Science ®Google Scholar
• Liu C, Karam R, Zhou Y, et al. The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. Nat Med. 2014;20(6):596–598. doi:10.1038/nm.3548
   PubMed Web of Science ®Google Scholar
• Nasif S, Colombo M, Uldry A-C, et al. Inhibition of nonsense-mediated mRNA decay reduces the tumorigenicity of human fibrosarcoma cells. NAR Cancer. 2023;5(3):zcad048. doi:10.1093/narcan/zcad048
   PubMedGoogle Scholar
• Yao W, Yao Y, He W, et al. PABPC1 promotes cell proliferation and metastasis in pancreatic adenocarcinoma by regulating COL12A1 expression. Immun Inflamm Dis. 2023;11(7):e919. doi:10.1002/iid3.919
   PubMed Web of Science ®Google Scholar
• Wang Q, Wang Z, Bao Z, et al. PABPC1 relevant bioinformatic profiling and prognostic value in gliomas. Future Oncol. 2020;16(1):4279–4288. doi:10.2217/fon-2019-0268
   PubMed Web of Science ®Google Scholar
• Fan S, Zhang S, Kong D, et al. Integrative multi-omics analysis of identified ferroptosis-marker RPL8 as a candidate oncogene correlates with poor prognosis and immune infiltration in liver cancer. Comb Chem High Throughput Screen. 2023;26(7):1298–1310. doi:10.2174/1386207325666220823122942
   PubMed Web of Science ®Google Scholar
• Boehm V, Kueckelmann S, Gerbracht JV, et al. SMG5-SMG7 authorize nonsense-mediated mRNA decay by enabling SMG6 endonucleolytic activity. Nat Commun. 2021;12(1):3965. doi:10.1038/s41467-021-24046-3
   PubMed Web of Science ®Google Scholar
• Yang L. Pan-cancer analysis of the prognostic and immunological role of SMG5: a biomarker for cancers. Oncology. 2023;2023:1.
   Google Scholar
• Anders KR, Grimson A, Anderson P. SMG-5, required for C. elegans nonsense-mediated mRNA decay, associates with SMG-2 and protein phosphatase 2A. EMBO j. 2003;22(3):641–650. doi:10.1093/emboj/cdg056
   PubMed Web of Science ®Google Scholar
• Huang L, Low A, Damle SS, et al. Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations. Genome Biol. 2018;19(1):4. doi:10.1186/s13059-017-1386-9
   PubMedGoogle Scholar
• Yi Z, Arvola RM, Myers S, et al. Mammalian UPF3A and UPF3B can activate nonsense-mediated mRNA decay independently of their exon junction complex binding. EMBO j. 2022;41(10):e109202. doi:10.15252/embj.2021109202
   PubMed Web of Science ®Google Scholar
• Xu J, Ma H, Shan B. Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: a pan-cancer analysis. PLoS One. 2022;17(10):e0273163. doi:10.1371/journal.pone.0273163
   PubMed Web of Science ®Google Scholar
• Matter MS, Decaens T, Andersen JB, et al. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol. 2014;60(4):855–865. doi:10.1016/j.jhep.2013.11.031
   PubMed Web of Science ®Google Scholar
• Pastor F, Kolonias D, Giangrande PH, et al. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature. 2010;465(7295):227–230. doi:10.1038/nature08999
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xie X, Yeganeh PN, et al. Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown. Proc Natl Acad Sci U S A. 2021;118:9.
   Web of Science ®Google Scholar
• Meraviglia-Crivelli D, Villanueva H, Menon AP, et al. A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression. Mol Ther Nucleic Acids. 2022;29:413–425. doi:10.1016/j.omtn.2022.07.017
   PubMedGoogle Scholar
• Pawlicka K, Kalathiya U, Alfaro J. Nonsense-Mediated mRNA decay: pathologies and the potential for novel therapeutics. Cancers. 2020;12(3):765. doi:10.3390/cancers12030765
   PubMed Web of Science ®Google Scholar
• Wakiyama H, Masuda T, Motomura Y, et al. Cytolytic Activity (CYT) score is a prognostic biomarker reflecting host immune status in hepatocellular carcinoma (HCC). Anticancer Res. 2018;38(12):6631–6638. doi:10.21873/anticanres.13030
   PubMed Web of Science ®Google Scholar
• Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity. 2019;50(4):907–923. doi:10.1016/j.immuni.2019.03.025
   PubMed Web of Science ®Google Scholar
• Lindeboom RG, Supek F, Lehner B. The rules and impact of nonsense-mediated mRNA decay in human cancers. Nat Genet. 2016;48(10):1112–1118. doi:10.1038/ng.3664
   PubMed Web of Science ®Google Scholar
• Supek F, Lehner B, Lindeboom RGH. To NMD or not to NMD: nonsense-Mediated mRNA decay in cancer and other genetic diseases. Trends Genet. 2021;37(7):657–668. doi:10.1016/j.tig.2020.11.002
   PubMed Web of Science ®Google Scholar